Inspira Technologies Oxy B.H.N. Ltd. (IINN)
| Market Cap | 18.52M -6.1% |
| Revenue (ttm) | 289,000 |
| Net Income | -13.22M |
| EPS | -0.45 |
| Shares Out | 43.58M |
| PE Ratio | n/a |
| Forward PE | 3.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 273,730 |
| Open | 0.4100 |
| Previous Close | 0.4070 |
| Day's Range | 0.4100 - 0.4600 |
| 52-Week Range | 0.3353 - 1.6500 |
| Beta | 2.33 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+370.7%) |
| Earnings Date | Mar 26, 2026 |
About IINN
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure in Israel. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. It also offers additive manufactured electronics platform that enables 3D architecture for systems operating in dilution cryostats. The company was formerly known as Insense Medical Ltd. ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for IINN stock is "Strong Buy" and the 12-month stock price target is $2.0.
News
Inspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform
RA'ANANA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”) today announced its entry into the quantum computing sector, targ...
Inspira Technologies Announces Acquisition of the AME Platform from Nano Dimension
The transaction includes intellectual property , customer-related assets and commercial operations, positioning the Company for the next stage of its strategy
Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase
RA'ANANA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies...
Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates
Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale
Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
Ra'anana, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and dia...
Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
RA'ANANA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and dia...
Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks
RA'ANANA, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies,” “Inspira,” or the “Company”), a pioneer in innovative life-supp...
Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement
RA'ANANA, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagn...
Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market
Company's validation confirms 94.2% accuracy for blood pCO₂ measurement, pivot to standalone configuration opens immediate commercial pathway to global installed base of heart-lung machines and extrac...
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders
RA'ANANA, Israel, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technol...
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protectio...
Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
All-share acquisition positions Inspira to expand into a multi-billion dollar diagnostics market with a development-ready innovative technology; transaction structured to include significant protectio...
Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones
Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026 Revenues Relating to the Binding Purchase Orders Expected to be Received and Recognized in 2026
Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution
RA'ANANA, Israel, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-supp...
Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology
RA'ANANA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and...
Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission
RA'ANANA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and...
Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion
RA'ANANA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and...
Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira's Global Ecosystem
RA'ANANA, Israel, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and...
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and...
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Inspira delivered major milestones throughout and following the six months ended June 30, 2025, including the receipt of $49.5 million in binding purchase orders, clinical validation in leading hospit...
Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance
RA'ANANA, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support an...
Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market
RA'ANANA, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and...
Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years
RA'ANANA, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and...
Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives
RA'ANANA, Israel, July 31, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and...
Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement
RA'ANANA, Israel, July 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and...